EOCENE LTD
EOCNNASDAQ๐ #5185 by market capUS Equity
$2.34โผ $0.15 (โ6.02%)
Market closed ยท at closeTrack EOCN
Get earnings, price moves & breaking news on Telegram
24hโผ 6.0%
7dโผ 6.0%
14dโผ 17.0%
30dโผ 27.6%
ytdโผ 61.6%
1yโผ 64.8%
๐ฆMarket Cap
$2M
Small Cap
๐Revenue Growth (YoY)
โ
๐Gross Margin
โ
๐ตFCF Margin
โ
โ๏ธP/S Ratio
โ
Otter Score
โ
Insufficient data
Trading Snapshot
- Day Range
- $2.34 โ $2.34
- 52-Week Range
- $1.75 โ $10.08
- Volume (shares)
- 301
- Avg Volume (shares)
- โ
- Shares Outstanding
- 1.0M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- โ
- Dividend Yield
- โ
EOCENE LTD
EOCNFinancial Trends
Financial history unavailable.
About EOCENE LTD
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
โ/100
Analyst data unavailable.
Latest News & Updates
News unavailable.